It has routinely established a reduced binding in patients with PD [90] and can aid clinicians in diagnosis and monitoring, as the decreased ligand binding to the DAT correlates with disease progression and clinical scoring [91,92]. This evidence concerns the gene SLC6A3 and Parkinson disease.